Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States

Published on January 8, 2021

Find interim clinical considerations for the use of Pfizer-BioNTech COVID-19 Vaccine.

Continue reading on website
Other news

ACIP Evidence to Recommendations for Use of Moderna COVID-19 Vaccine under an Emergency Use Authorization

January 8, 2021
Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 vaccine in persons aged 16 years and older for prevention of COVID-19.

Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Moderna COVID-19 Vaccine

January 8, 2021
Information about reactions and adverse events reported by recipients of the Pfizer-BioNTech COVID-19 Vaccine